SPOTLIGHT: Merck KGaA clears way for Bayer

Merck KGaA has agreed to sell its 21.8 percent stake in Schering to Bayer, clearing the way for Bayer's takeover. Article (WSJ sub. req.)

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.